Amneal Pharmaceuticals/$AMRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amneal Pharmaceuticals
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Ticker
$AMRX
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
8,300
ISIN
US03168L1052
Website
AMRX Metrics
BasicAdvanced
$2.6B
-
-$0.04
1.17
-
Price and volume
Market cap
$2.6B
Beta
1.17
52-week high
$9.23
52-week low
$6.50
Average daily volume
1.7M
Financial strength
Current ratio
1.404
Quick ratio
0.801
Long term debt to equity
-3,775.037
Total debt to equity
-4,343.399
Interest coverage (TTM)
1.46%
Profitability
EBITDA (TTM)
604.873
Gross margin (TTM)
36.45%
Net profit margin (TTM)
-0.46%
Operating margin (TTM)
12.86%
Effective tax rate (TTM)
44.10%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
6.67%
Return on equity (TTM)
-85.32%
Valuation
Price to revenue (TTM)
0.921
Price to book
-19.82
Price to tangible book (TTM)
-1.86
Price to free cash flow (TTM)
11.169
Free cash flow yield (TTM)
8.95%
Free cash flow per share (TTM)
75.30%
Growth
Revenue change (TTM)
13.42%
Earnings per share change (TTM)
-94.64%
3-year revenue growth (CAGR)
10.49%
3-year earnings per share growth (CAGR)
52.83%
What the Analysts think about AMRX
Analyst ratings (Buy, Hold, Sell) for Amneal Pharmaceuticals stock.
Bulls say / Bears say
Amneal Pharmaceuticals has demonstrated consistent revenue growth, with a 17% year-over-year increase in 2024, indicating strong operational performance. (Seeking Alpha)
Analysts have set an average 12-month price target of $11.75 for AMRX, suggesting a potential upside of over 40% from the current price. (Simply Wall St)
The company's strategic focus on biosimilars and specialty drugs positions it well in high-growth markets, potentially driving future revenue. (Seeking Alpha)
Amneal reported a net loss of $13.05 million in the trailing twelve months, raising concerns about profitability. (Stock Analysis)
The company's return on assets stands at -5.24%, indicating inefficiencies in asset utilization. (Financhill)
Amneal's total debt of $2.5 billion could pose financial risks, especially if revenue growth slows. (Financhill)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
AMRX Financial Performance
Revenues and expenses
AMRX Earnings Performance
Company profitability
AMRX News
AllArticlesVideos
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
GlobeNewsWire·2 weeks ago
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
GlobeNewsWire·4 weeks ago
Amneal to Participate at Upcoming Investor Conferences in June
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amneal Pharmaceuticals stock?
Amneal Pharmaceuticals (AMRX) has a market cap of $2.6B as of July 08, 2025.
What is the P/E ratio for Amneal Pharmaceuticals stock?
The price to earnings (P/E) ratio for Amneal Pharmaceuticals (AMRX) stock is 0 as of July 08, 2025.
Does Amneal Pharmaceuticals stock pay dividends?
No, Amneal Pharmaceuticals (AMRX) stock does not pay dividends to its shareholders as of July 08, 2025.
When is the next Amneal Pharmaceuticals dividend payment date?
Amneal Pharmaceuticals (AMRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Amneal Pharmaceuticals?
Amneal Pharmaceuticals (AMRX) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.